Monica Heger tracks trends in next-generation sequencing for research and clinical applications for GenomeWeb.
The team has developed a method to test for inherited disorders prenatally and plan to conduct a larger trial and eventually offer it as a clinical test.
The researchers developed a qPCR test that analyzes microRNAs associated with ovarian cancer and plan to run a retrospective trial of the assay on biobanked samples.
Natera said its liquid biopsy assay Signatera is well suited for the immuno-oncology field, particularly pharmaceutical companies developing personalized vaccines.
Veracyte attributed its lower Afirma sales in part to slowing down the rollout of an updated version of the test that relies on RNA sequencing.
The team has licensed the technology to startup Cygnus Biosciences and is working with the firm to increase its throughput and commercialize it.
The firm recently hired Kathy Ordoñez as chief commercial officer, who plans to develop clinical opportunities for the company.
The researchers plan to use the method in clinical research, designing noninvasive prenatal tests for single-gene disorders like beta thalassemia.
The researchers are working to develop portable sequencing solutions for outbreak surveillance and infectious disease diagnostics.
Startup TwinStrand Biosciences has licensed the method and is working on developing targeted assays, including for early detection of ovarian cancer.
Sales to clinical customers grew by 35 percent in the quarter and Illumina expects further growth following United Healthcare's decision to cover exome sequencing.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.